Skip to content

Study · Non-randomized trial · 2008

7 results

Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept.

Faradji RN, Tharavanij T, Messinger S, Froud T, Pileggi A, Monroy K, Mineo D, Baidal DA, Cure P, Ponte G, Mendez AJ, Selvaggi G, Ricordi C, Alejandro R

Transplantation1 Dec 2008Cited by 70 (Europe PMC)

PMID19104401 (opens in a new tab)PMCIDPMC2759384 (opens in a new tab)DOI10.1097/tp.0b013e31818fe448 (opens in a new tab)PepBankPUB-19104401
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In islet recipients, acute exenatide during intravenous glucose testing improved first-phase insulin release.

    In plain wordsAcute exenatide improved early insulin release during intravenous glucose tests in islet recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFirst-phase insulin release
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute effects of EXN during mixed meal tolerance test and intravenous glucose tolerance test results in improved first and second phase insulin release in response to intravenous glucose tolerance test and suppressed postprandial hyperglucagonemia after mixed meal tolerance test.
    2 context sentences
    Summary · context
    To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.
    Summary · context
    Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).
  2. 02HumanNon-randomized trialEfficacy outcome

    In islet recipients, acute exenatide during intravenous glucose testing improved second-phase insulin release.

    In plain wordsAcute exenatide improved later insulin release during intravenous glucose tests in islet recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSecond-phase insulin release
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute effects of EXN during mixed meal tolerance test and intravenous glucose tolerance test results in improved first and second phase insulin release in response to intravenous glucose tolerance test and suppressed postprandial hyperglucagonemia after mixed meal tolerance test.
    2 context sentences
    Summary · context
    To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.
    Summary · context
    Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).
  3. 03HumanNon-randomized trialEfficacy outcome

    In islet recipients, acute exenatide suppressed postprandial hyperglucagonemia during mixed meal testing.

    In plain wordsAcute exenatide reduced excessive after-meal glucagon in islet recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial hyperglucagonemia
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Acute effects of EXN during mixed meal tolerance test and intravenous glucose tolerance test results in improved first and second phase insulin release in response to intravenous glucose tolerance test and suppressed postprandial hyperglucagonemia after mixed meal tolerance test.
    2 context sentences
    Summary · context
    To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.
    Summary · context
    Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 04HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In islet recipients, exenatide plus etanercept increased long-term insulin independence versus supplemental infusion controls.

    In plain wordsExenatide plus etanercept increased insulin independence compared with supplemental infusion alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin independence
    Study

    n = 9

    Comparator
    Supplemental islet infusion without exenatide and etanercept
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Insulin independence
    100%
    SI-EXN at 18 months
    Insulin independence
    20%
    SI-control at 18 months

    Source sentences

    Summary
    Long-term II (18 months) was observed in 100% of SI-EXN and in 20% of SI-control (P=0.04).
    2 context sentences
    Summary · context
    To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.
    Summary · context
    Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 05HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In islet recipients, supplemental infusion with exenatide and etanercept produced better responses than control infusion at 3 months.

    In plain wordsResponses were better with exenatide and etanercept than with control infusion at 3 months.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseResponse at 3 months
    Study

    n = 9

    Comparator
    Supplemental islet infusion without exenatide and etanercept
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Comparison of SI-EXN and SI-control groups demonstrated better responses in SI-EXN subjects at 3 months post-SI.
    2 context sentences
    Summary · context
    To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.
    Summary · context
    Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 06HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In islet recipients, exenatide plus etanercept sustained function better than control infusion during follow-up.

    In plain wordsFunction persisted better with exenatide and etanercept than with control infusion.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSustained graft function
    Study

    n = 9

    Comparator
    Supplemental islet infusion without exenatide and etanercept
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    During the 18 months of follow-up, function was sustained in the SI-EXN subjects better than in SI-controls.
    2 context sentences
    Summary · context
    To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.
    Summary · context
    Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 07HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome

    In islet recipients, supplemental infusion with exenatide and etanercept restored function better than initial infusion.

    In plain wordsFunction improved more after supplemental infusion with exenatide and etanercept than after initial infusion.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseRestoration of graft function
    Study

    n = 4

    Comparator
    Initial islet infusion
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    SI-EXN subjects demonstrated restoration of function better than that seen after initial islet infusions.
    2 context sentences
    Summary · context
    To improve the engraftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusion, and long-term EXN treatment were tested in a non-randomized pilot clinical trial.
    Summary · context
    Patients with GDF received SI under Edmonton-like immunosuppression with daclizumab induction, either without interventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.